Showing results (71-80 of 85) with videos related to
Sort By:
Pageof 9
Oncoimmunology|July 22, 2021
Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective studyKenji Morimoto, Junji Uchino, Takashi Yokoi, et al.Journal of Cancer Research and Clinical Oncology|September 12, 2021
Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective studyKenji Morimoto, Junji Uchino, Takashi Yokoi, et al.Lung Cancer (Amsterdam, Netherlands)|September 20, 2021
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)Go Saito, Yuko Oya, Yoshihiko Taniguchi, et al.Lung Cancer (Amsterdam, Netherlands)|September 9, 2021
Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancerKenji Morimoto, Tadaaki Yamada, Takashi Yokoi, et al.Cancer Science|June 13, 2020
Tumor-associated macrophage-derived inflammatory cytokine enhances malignant potential of malignant pleural mesotheliomaDaisuke Horio, Toshiyuki Minami, Hidemi Kitai, et al.The Lancet. Oncology|October 12, 2019
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 studyRina Hui, Mustafa Özgüroğlu, Augusto Villegas, et al.Chest|June 6, 2022
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World SettingYuki Sato, Hiromitsu Sumikawa, Ryota Shibaki, et al.European Journal of Cancer (Oxford, England : 1990)|April 23, 2021
Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort studyDaichi Fujimoto, Satoru Miura, Kenichi Yoshimura, et al.European Journal of Cancer (Oxford, England : 1990)|November 8, 2021
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)Yoshihiko Sakata, Shinya Sakata, Yuko Oya, et al.JAMA Network Open|February 24, 2023
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial EligibilityDaichi Fujimoto, Takeshi Morimoto, Motohiro Tamiya, et al.Pageof 9